These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38403964)

  • 1. Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy against Glioblastoma Multiforme.
    Du K; Li X; Feng F
    ACS Appl Bio Mater; 2024 Mar; 7(3):1810-1819. PubMed ID: 38403964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
    Du K; Xia Q; Sun J; Feng F
    ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
    Li X; Shao F; Sun J; Du K; Sun Y; Feng F
    ACS Appl Mater Interfaces; 2019 Nov; 11(45):41935-41945. PubMed ID: 31644262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.
    Wang X; Hu A; Du K; Feng F
    ACS Appl Bio Mater; 2021 Nov; 4(11):8004-8012. PubMed ID: 35006781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
    Jatyan R; Singh P; Sahel DK; Karthik YG; Mittal A; Chitkara D
    J Control Release; 2022 Oct; 350():494-513. PubMed ID: 35985493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
    Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY
    FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
    Lan F; Pan Q; Yu H; Yue X
    J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific transport of temozolomide does not override DNA repair-mediated chemoresistance.
    Bahrami K; Kärkkäinen J; Bibi S; Huttunen J; Tampio J; Montaser AB; Moody CL; Lehtonen M; Rautio J; Wheelhouse RT; Huttunen KM
    Eur J Pharm Sci; 2024 Apr; 195():106661. PubMed ID: 38052257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
    Petrenko D; Chubarev V; Syzrantsev N; Ismail N; Merkulov V; Sologova S; Grigorevskikh E; Smolyarchuk E; Alyautdin R
    Molecules; 2022 May; 27(11):. PubMed ID: 35684445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
    Bouzinab K; Summers HS; Stevens MFG; Moody CJ; Thomas NR; Gershkovich P; Weston N; Ashford MB; Bradshaw TD; Turyanska L
    ACS Appl Mater Interfaces; 2020 Mar; 12(11):12609-12617. PubMed ID: 32073826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
    Salvatori L; Malatesta S; Illi B; Somma MP; Fionda C; Stabile H; Fontanella RA; Gaetano C
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
    Ramalho MJ; Andrade S; Coelho MÁN; Loureiro JA; Pereira MC
    Eur J Pharm Biopharm; 2019 Mar; 136():156-163. PubMed ID: 30682492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
    Jatyan R; Sahel DK; Singh P; Sakhuja R; Mittal A; Chitkara D
    J Control Release; 2023 Jul; 359():161-174. PubMed ID: 37182806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma.
    Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D
    J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.